victoza glp 1 First Generic of Once-Daily GLP-1 Injection Approved for Diabetes Since the introduction of Liraglutide

Using an integrated ligand and structure-based virtual screening pipeline, explicitly combining complementary ligand-based descriptors, multi-fingerprint similarity, electrostatic similarity, pharmacophore modeling, and multi-conformation docking under a consensus-driven selection strategy, we were able to identify three chemically distinct classes of GLP-1R agonist candidates: GQB47810, a non-peptidic molecule

The more meaningful question is not: Do patients regain weight after stopping GLP-1s? It is: How should we transition patients from pharmacologic support to long-term weight maintenance? Obesity is a chronic disease

Summary In summary, GLP-1 RA based therapies are being rigorously studied in management of MASLD in particular more advanced stages and likely will become foundational therapies in the future.

Average cost-sharing for a one-month supply of GLP-1 medications ranged from $61 to $93 in 2023